Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.

Nature clinical practice. Oncology - 1 Jan 2006

Choong Nicholas W, Dietrich Sascha, Seiwert Tanguy Y, Tretiakova Maria S, Nallasura Vidya, Davies Gareth C, Lipkowitz Stanley, Husain Aliya N, Salgia Ravi, Ma Patrick C

Abstract excerpt

BACKGROUND: A 70-year-old Japanese-American woman who had never smoked was diagnosed with stage IV non-small-cell lung cancer with rib metastases. She had previously been well and she had no family history of malignancy. While receiving treatment with erlotinib, an epidermal growth factor receptor small-molecule inhibitor, she progressed and developed new brain metastases. She failed further chemotherapy...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Bone Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Meningeal Neoplasms

Share to Quinazolines

Share to Treatment Failure

Source

Identifiers

PMID: 16407879
DOI: 10.1038/ncponc0400

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.PMID 16407879Read ↗

Successful treatment with weekly high-dose erlotinib against meningeal metastases from epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma.Semantic proximity Read ↗

High-Dose Furmonertinib in Patients With EGFR-Mutated NSCLC and Leptomeningeal Metastases: A Prospective Real-World Study.Semantic proximity Read ↗

Combination treatment with bevacizumab plus erlotinib for meningeal carcinomatosis of afatinib-resistant EGFR mutated lung cancer without T790M mutation: a case report.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.Semantic proximity Read ↗

Significant benefit of high-dose furmonertinib in the treatment of leptomeningeal metastases from non-small-cell lung cancer with EGFR ex19Del mutation: Two case reports and a literature reviewSemantic proximity Read ↗

Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report.Semantic proximity Read ↗

Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report.Semantic proximity Read ↗

Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).Semantic proximity Read ↗

CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.Semantic proximity Read ↗

Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.Semantic proximity Read ↗

Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer.Semantic proximity Read ↗

Research progress on meningeal metastasis of lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.